Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics is redefining autoimmune care with CD19-targeted CAR T cells, yet its SEC disclosures weave together trial endpoints, collaboration milestones, and dilution details that can bury critical signals. If you’ve ever searched dozens of PDFs for one R&D expense line or an FDA hold notice, you already know the pain.
Stock Titan removes that friction. Our AI reads every submission the second it hits EDGAR, then delivers Kyverna Therapeutics SEC filings explained simply. Drill into a Kyverna Therapeutics annual report 10-K simplified to see cash runway and pipeline updates, or open a Kyverna Therapeutics quarterly earnings report 10-Q filing for side-by-side trend analysis. Need real-time insider sentiment? We surface Kyverna Therapeutics insider trading Form 4 transactions and flag any Kyverna Therapeutics Form 4 insider transactions real-time. Material news is never missed—each Kyverna Therapeutics 8-K material events explained highlights clinical trial pauses, partnership payments, or equity offerings in plain language.
Professionals use the platform to:
- Track R&D spend vs. cash on hand through our Kyverna Therapeutics earnings report filing analysis.
- Monitor management incentives via Kyverna Therapeutics proxy statement executive compensation.
- Spot buying or selling trends with Kyverna Therapeutics executive stock transactions Form 4.
- Save hours by understanding Kyverna Therapeutics SEC documents with AI instead of wading through 250-page reports.
Whether you’re preparing a valuation model or checking compliance, Stock Titan’s AI-powered summaries, expert context, and real-time alerts make complex biotech filings effortless.
Kyverna Therapeutics (ticker KYTX) filed a Form 4 disclosing that its Chief Financial Officer, Marc Grasso, received an equity award on 30 June 2025. The transaction involves a single grant of 450,000 stock options with an exercise price of $3.07 and an expiration date of 30 June 2035.
The vesting schedule follows a standard four-year pattern: 25 % (112,500 options) vests on 30 June 2026, after which 1⁄48 of the total options (9,375 shares) vest monthly for the next 36 months, contingent on Grasso’s continued employment. The filing shows direct ownership (D) of the derivative security, and no other changes to common-stock holdings were reported.
This award aligns the CFO’s incentives with long-term shareholder value creation and signals a retention commitment by the company. If fully exercised, the award would add up to 450,000 new common shares to the float, a modest potential dilution given Kyverna’s recent post-IPO share count of roughly 55-60 million (based on prior filings). No cash transactions were reported, and the filing contains no earnings or operational updates.
Kronos Bio, Inc. (KRON) filed a Form 15-12G with the U.S. SEC on 30 June 2025, certifying the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and suspending the company’s duty to file reports under Sections 13 and 15(d).
The company relied on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i), disclosing an approximate holder count of one. No other securities remain subject to reporting obligations. The notice was signed by Chief Financial Officer Michael Hearne.
Once the Form 15 becomes effective, Kronos Bio will no longer submit periodic filings such as Forms 10-K, 10-Q or 8-K, significantly reducing public disclosure and potentially affecting liquidity for remaining shareholders.
FAQ
What is the current stock price of Kyverna Therapeutics (KYTX)?
What is the market cap of Kyverna Therapeutics (KYTX)?
What is Kyverna Therapeutics?
What is KYV-101?
How does CAR T-cell therapy work in autoimmune diseases?
Which autoimmune conditions are being targeted by Kyverna’s therapies?
What sets Kyverna’s approach apart from other immunotherapies?
How does the company support its clinical development?
What is the significance of targeting CD19 in autoimmune diseases?
How does Kyverna maintain a patient-centered focus?
